title: Seroreactivity to Helicobacter pylori antigens as a risk indicator of gastric cancer.
abstract: BACKGROUND
  Multiple etiologic factors are suspected to cause gastric cancer, the most important of which is infection with virulent types of Helicobacter pylori.
  
  
  METHODS
  We have compared 102 gastric cancer patients with 122 non-ulcer, non-cancer dyspeptic patients. Gastric specimens were evaluated for H. pylori infection by tissue-based detection methods. Patient sera underwent antigen-specific ELISA and western blotting using a Helicoblot 2.1 kit and antibody responses to various H. pylori antigens were assessed.
  
  
  RESULTS
  The absolute majority (97-100%) of both groups were H. pylori seropositive. Multivariate regression analysis demonstrated serum antibodies to the low molecular weight 35kDa protein to be protective and reduce the risk of gastric cancer by 60% (OR:0.4; 95%CI:0.1-0.9). Conversely, seroreactivity to the 89kDa (VacA) protein was significantly higher in gastric cancer patients (OR:2.7; 95%CI:1.0-7.1). There was a highly significant association (p<0.001) between seroreactivity to the 116kDa (CagA) and 89kDa (VacA) proteins, and double positive subjects were found at nearly five fold (OR:4.9; 95%CI:1.0-24.4) enhanced risk of gastric cancer as compared to double negative subjects.
  
  
  CONCLUSIONS
  Seroreactivity to H. pylori low (35kDa) and high (116kDa/89kDa) molecular weight antigens were respectively revealed as protective and risk indicators for gastric cancer.
authors.affiliation: HPGC Group, Medical Biotechnology Department, Biotechnology Research Center, Tehran, Iran.
authors.forename: Najmeh
authors.initials: N
authors.lastname: Karami
authors.forename: Yeganeh
authors.initials: Y
authors.lastname: Talebkhan
authors.forename: Samaneh
authors.initials: S
authors.lastname: Saberi
authors.forename: Maryam
authors.initials: M
authors.lastname: Esmaeili
authors.forename: Akbar
authors.initials: A
authors.lastname: Oghalaie
authors.forename: Afshin
authors.initials: A
authors.lastname: Abdirad
authors.forename: Ehsan
authors.initials: E
authors.lastname: Mostafavi
authors.forename: Mahmoud Eshagh
authors.initials: ME
authors.lastname: Hosseini
authors.forename: Mohammad Ali
authors.initials: MA
authors.lastname: Mohagheghi
authors.forename: Marjan
authors.initials: M
authors.lastname: Mohammadi
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000453:epidemiology / Q000209:etiology*; D000328:Adult; D000368:Aged; D000907:Antibodies, Bacterial / Q000097:blood*; D000942:Antigens, Bacterial / Q000276:immunology*; D015153:Blotting, Western; D016022:Case-Control Studies; D004415:Dyspepsia / Q000097:blood / Q000453:epidemiology / Q000209:etiology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D016481:Helicobacter Infections / Q000150:complications / Q000276:immunology* / Q000382:microbiology; D016480:Helicobacter pylori / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000097:blood / Q000453:epidemiology / Q000209:etiology*
chemical_list: D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial